pd-l1 inhibitor incb099280
pd-l1 inhibitor incb099280: 7 clinical trials tracked.
pd-l1 inhibitor incb099280 evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about pd-l1 inhibitor incb099280, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trial Registry Records (7)
An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants
Primary endpoint: Total Recovery (Urine + Feces) of the Administered Radioactivity
A Pilot Study of Neoadjuvant INCB099280 in Patients With Hepatocellular Carcinoma Awaiting Liver Transplant
Primary endpoint: Acute Cellular Rejection of Liver Transplant Attributed to Study Therapy
A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Primary endpoint: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Primary endpoint: Number of Participants With Dose-limiting Toxicities (DLTs)
A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Primary endpoint: Objective response rate (ORR)
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma
Primary endpoint: Objective response rate (ORR)
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
Primary endpoint: Number of treatment-emergent adverse events